X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
USFDA approved generic version of Amantadine Hydrochloride, a NMDA inhibitor, which is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Symmetrel-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2022
Details:
Through the acquisition, Bora will commercialize Amantadine HCl-Generic, which is an NMDA receptor inhibitor. It is indicated for the treatment of influenza A infections and Parkinsonism.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Amantadine HCl-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bora Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 01, 2024
Details:
Through the acquisition, Bora gains Upsher-Smith’s product portfolio, including Amantadine hydrochloride, indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Amantadine HCl-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bora Pharmaceuticals
Deal Size: $210.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 18, 2024
Details:
Acquistion will strengthens Parkinson’s disease portfolio with GOCOVRI (amantadine) extended release capsules, the first and only FDA-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Gocovri
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Supernus Pharmaceuticals
Deal Size: $450.0 million Upfront Cash: $450.0 million
Deal Type: Acquisition November 24, 2021
Details:
The transaction will provide Supernus with two marketed products: GOCOVRI (amantadine) extended release capsules, indicated for both OFF and dyskinesia in patients with Parkinson’s disease and Osmolex ER (amantadine) tablets, approved for Parkinson’s disease.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Gocovri
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Supernus Pharmaceuticals
Deal Size: $450.0 million Upfront Cash: $450.0 million
Deal Type: Acquisition October 11, 2021
Details:
At week 12, participants treated with GOCOVRI reported statistically significant improvements in motor control for daily activities compared to placebo (least-squares mean changes from baseline of –3.4 points for GOCOVRI and –1.4 for placebo).
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Gocovri
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
Details:
Patients enrolled in the pivotal trials increased daily ON time without dyskinesia by 2.9 hours with GOCOVRI compared to placebo, through the reduction of both OFF time and dyskinesia.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Gocovri
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Details:
Through this acquisition, OSMOLEX ER joins the Adamas portfolio which includes GOCOVRI® extended-release capsules for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy with or without concomitant dopaminergic medications.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Osmolex ER
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adamas Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 05, 2021
Details:
Under the terms of the agreement, both parties will drop their respective claims relating to the patent litigation, and Adamas will acquire the global rights to OSMOLEX ER for $7.5 million.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Osmolex ER
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adamas Pharmaceuticals
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Agreement December 02, 2020
Details:
Adamas has proposed to include GOCOVRI as an appropriate therapy for the treatment of OFF episodes in PD patients receiving levodopa. The clinical evidence supporting GOCOVRI’s effect on OFF time was demonstrated in two large pivotal Phase 3 trials.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Gocovri
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
